Compositions and methods of using compositions with accelerated

Details Compositions and methods of using compositions with accelerated Compositions and methods of using compositions with accelerated

1997-09-23

1999-12-21

Saunders, David

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

514487, 514546, 514653, 560 29, 560163, 564223, 564355, A61K 31135

Patent

active

060045655

ABSTRACT:
The methods and compositions of the invention and the compounds used in the invention involve a novel immunosuppression mechanism, accelerated lymphocyte homing immunosuppression (ALH-immunosuppression). For example, the compound FTY720 specifically directs lymphocytes to the peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches. By reversibly sequestering lymphocytes in these tissues, the compounds can inhibit an immune response in a mammal. Understanding these mechanisms provides a novel immunosuppression therapy that can synergistically interact with other immunosuppressive compounds. Screening methods for identifying similar ALH-immunosuppression compounds are also described. The invention allows better treatments and therapies wherever an immunosuppression regimen is desired.

REFERENCES:
patent: 5037958 (1991-08-01), Hashimoto
patent: 5219884 (1993-06-01), Fugita
patent: 5604229 (1997-02-01), Fujita et al.
patent: 5686479 (1997-11-01), Okumoto
patent: 5719175 (1998-02-01), Fugita
P. Cresswell, "Assembly, Transport, and Function of MHC Class II Molecules," Annu. Rev. Immunol., vol. 12, pp. 259-293 (1994).
M.R. Jackson et al., "Assembly and Intracellular Transport of MHC Class I Molecules," Annu. Rev. Cell Biol., vol. 9, pp. 207-235 (1993).
J.C. Howard, "Supply and transport of peptides presented by class I MHC molecules," Curr. Opin. Immunol., vol. 7, pp. 69-76 (1995).
B.D. Kahan, "Medical Intelligence, Drug Therapy, Cyclosporine," The New England Journal of Medicine, vol. 321, No. 25, pp. 1725-1738 (Dec. 21, 1989).
J. Fung et al., "A Randomized Trial of Primary Liver Transplantation Under Immunosuppression with FK 506 vs Cyclosporine," Transplantation Proceedings, vol. 23, No. 6, pp. 2977-2983 (Dec. 1991).
J.F. Borel et al., "Biological Effects of Cyclosporin A: A New Antilymphocytic Agent," Agents and Actions, vol. 6/4, pp. 468-475 (1976).
J. F. Borel, "Pharmacology of Cyclosporine (Sandimmune) IV. Pharmacological Properties in Vivo," Pharmacological Reviews, vol. 41, No. 3, pp. 259-371 (1989).
T. Kino et al., "FK-506, A Novel Immunosuppressant Isolated from a Streptomyces, I. Fermentation, Isolation and Physico-Chemical and Biological Characteristics," The Journal of Antibiotics, vol. 40, No. 9, pp. 1249-1255 (1987).
T. Kino et al., "FK-506, A Novel Immunosuppressant Isolated from a Streptomyces, II. Immunosuppressive Effect of FK-506 In Vitro," The Journal of Antibiotics, vol. 40, No. 9, pp. 1256-1265 (Sep. 1987).
N. Inamura et al., "Prolongation of Skin Allograft Survival in Rats by a Novel Immunosuppressive Agent, FK506," Transplantation, vol. 45, No. 1, pp. 206-209 (Jan. 1988).
J. Liu et al., "Calcineurin Is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes," Cell, vol. 66, pp. 807-815, (Aug. 23, 1991).
Y. Kokado et al., "Low-dose ciclosporin mizoribine and prednisolone in renal transplantation: A New triple-drug therapy," Clin. Transplantation, vol. 4, pp. 191-197 (1990).
T. Fujita et al., "Fungal Metabolites, Part 11. A Potent Immunosuppressive Activity Found in Isaria sinclairii Metabolite," The Journal of Antibiotics, vol. 47, No. 2, pp. 208-215 (Feb. 1994).
T. Fujita et al., "Fungal Metabolites, Part 12. Potent Immunosuppressant, 14-Deoxomyriocin, (2S, 3R, 4R)--(E) -2-Amino-3,4-Dihydroxy-2-Hydroxymethyleicos-6-Enoic Acid and Structure-Activity Relationships of Myriocin Derivatives," The Journal of Antibiotics, vol. 47, No. 2, pp. 216-224 (Feb. 1994).
S. Sasaki et al., "Fungal Metabolites. Part 14. Novel Potent Immunosuppressants, Mycestericins, Produced by Mycelia sterilia," The Journal of Antibiotics, vol. 47, No. 4, pp. 420-433 (Apr. 1994).
H.ff.S. Davies et al., "Long-Term Survival of Kidney Allografts in Dogs After Withdrawal of Immunosuppression with Ciclosporin and Azathioprine," Eur. Surg. Res., vol. 21, pp. 65-75 (1989).
H. Amemiya et al., "Synergistic Effect of Cylcosporine and Mizoribine on Survival of Dog Renal Allografts," Transplantation, vol. 46, No. 5, pp. 768-771 (Nov. 1988).
M.L. Arbones et al., "Lymphocyte Homing and Leukocyte Rolling and Migration are Impaired in L-Selectin-Deficient Mice," Immunity, vol. 1, pp. 247-260 (Jul. 1994).
A. Hamann et al., "Role of .alpha..sub.4 -Integrins in Lymphocyte Homing to Mucosal Tissues in Vivo," Journal of Immunology, vol. 152, pp. 3282-3293 (1994).
Y. Imai et al., "Sulphation requirement for GlyCAM-1, an endothelial ligand for L-selectin," Nature, vol. 361, pp. 555-557 (Feb. 11, 1993).
T. B. Issekutz, "Inhibition of In Vivo Lymphocyte Migration to Inflammation and Homing to Lymphoid Tissues by the TA-2 Monoclonal Antibody," The Journal of Immunology, vol. 147, No. 12, pp. 4178-4184 (Dec. 15, 1991).
C. Berlin et al., ".alpha.4.beta.7 Integrin Mediates Lymphocyte Binding to the Mucosal Vascular Addressin MadCAM-1," Cell, vol. 74, pp. 185-195 (Jul. 16, 1993).
B.D. Kahan et al., "Preclinical Evaluation of a New Potent Immunosuppressive Agent, Rapamycin," Transplantation, vol. 52, No. 2, pp. 185-191 (Aug. 1991).
R. Schwartz et al., "Drug-induced Immunological Tolerance," Nature, vol. 183, p. 1682 (Jun. 13, 1959).
L.A. Turka et al., "Guanine Ribonucleotide Depletion Inhibits T Cell Activation," J. Clin. Invest., vol. 87, pp. 940-948 (Mar. 1991).
W.A. Lee et al., "Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization," Pharmaceutical Research, vol. 7, No. 2, pp. 161-166 (1990).
D.V. Cramer et al., "The Effect of a New Immunosuppressive Drug, Brequinar Sodium, on Heart, Liver, and Kidney Allograft Rejection in the Rat," Transplantation, vol. 53, No. 2, pp. 303-308 (Feb. 1992).
L.J. Picker et al., "Physiological and Molecular Mechanisms of Lymphocyte Homing," Ann. Rev. Immunol., vol. 10, pp. 561-591 (1992).
J.E. Miller et al., "A New Model of Heterotopic Rat Heart Transplantation with Application for In Vivo .sup.31 P Nuclear Magnetic Resonance Spectroscopy," Transplantation, vol. 39, No. 5, pp. 555-558 (May 1985).
M.J. Dallman et al., "Cytokine Gene Expression: Analysis using Northern Blotting, Polymerase Chain Reaction and in situ Hybridization," Immunological Reviews, No. 119, pp. 163-179 (1991).
M.J. Dallman et al., "Cytokine Gene Transcription in Vascularised Organ Grafts: Analysis Using Semiquantitative Polymerase Chain Reaction," J. Exp. Med., vol. 174, pp. 493-496 (Aug. 1991).
J. Wang et al., "Local Hormone Networks and Intestinal T Cell Homeostasis," Science, vol. 275, pp. 1937-1939 (Mar. 28, 1997).
European FK506 Multicentre Liver Study Group, "Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection", The Lancet, vol. 344, pp. 423-428 (Aug. 13, 1994).
T. Tanaka et al., "Characterization of a CD3-like Rat T Cell Surface Antigen Recognized by a Monoclonal Antibody," The Journal of Immunology, vol. 142, No. 8, pp. 2791-2795 (Apr. 15, 1989).
G.R. Woollett et al., "Molecular and antigenic heterogeneity of the rat leukocyte-common antigen from thymocytes and T and B lymphocytes," Eur. J. Immunol., vol. 15, pp. 168-173 (1985).
Y. Masaki et al., "Microchimerism and Heart Allograft Acceptance," Transplantation Proceedings, vol. 27, No. 1, pp. 148-150 (Feb. 1995).
C. Legendre et al., "Prediction of Successful Allograft Rejection Retreatment with OKT3," Transplantation, vol. 53, No. 1, pp. 87-90 (Jan. 1992).
T. Tamatani et al., Characterization of rat LECAM-1 (L-selectin) by the use of monoclonal antibodies and evidence for the presence of soluble LECAM-1 in rat sera, Eur. J. Immunol., vol. 23, pp. 2181-2188, (1993).
L.M. McEvoy et al., "Anti-CD43 inhibition of T Cell homing," J. Exp. Med., vol. 185, No. 8, pp. 1493-1498 (Apr. 21, 1997) (Abstract only).
T. Tamatani et al., "Characterization of the rat leukocyte integrin, CD11/CD18, by the use of LFA-1 subunit-specific monoclonal antibodies," Eur. J. Immunol., vol. 21, pp. 627-633 (1991).
A. Siegling et al., "A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats," Journal of Immunological Methods, vol. 177, pp. 23-28 (1994).
Copending U.S. Application Serial No. 08/801,390, filed Feb. 20, 1997.
Tetsu

Affiliated with

Also associated with

Rating

Compositions and methods of using compositions with accelerated does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods of using compositions with accelerated , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of using compositions with accelerated will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-502293